Cite
HARVARD Citation
Furie, R. et al. (n.d.). P130 Treatment of SLE with the immunoproteasome inhibitor KZR-616: results from the first 4 cohorts of the MISSION study, an open-label phase 1b dose escalation trial. Lupus science & medicine. p. A93. [Online].